Together with computational biology, the development of drugs targeting the SLC13A5 could be accelerated for potential therapeutics of carbohydrate and lipid metabolism disorders like diabetes, non-alcoholic fatty liver and obesity. The gene discussed is SLC13A5; the disease is obesity disorder.